Skip to content

In the BioHarmony Drug Report Database


Tavalisse, Tavlesse (fostamatinib) is a small molecule pharmaceutical. Fostamatinib was first approved as Tavalisse on 2018-04-17. It is used to treat thrombocytopenia in the USA. It has been approved in Europe to treat thrombocytopenia. Tavalisse's patent is valid until 2032-07-27 (FDA).
Trade Name Tavlesse
Common Name Fostamatinib
Indication thrombocytopenia
Drug Class Tyrosine kinase inhibitors; phosphoro-derivatives
Get full access now